Wednesday, May 2, 2012
Quark Pharmaceuticals Inc., of Fremont, Calif., said it amended its existing exclusive licensing agreement with Pfizer Inc., of New York, which enables Quark to perform a Phase IIa study assessing the effect of PF-655 on visual function in patients with moderate and advanced open-angle glaucoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.